Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. - Wikidata - wikimedia - TriplyDB

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

http://www.wikidata.org/entity/Q37532641

about

Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives Optimal management of hormone receptor positive metastatic breast cancer in 2016 Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant Antiestrogens: structure-activity relationships and use in breast cancer treatment Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers Cancer drug related cardiotoxicity during breast cancer treatment.High-dose toremifene for fulvestrant-resistant metastatic breast cancer: a report of two cases.Fulvestrant in advanced breast cancer: evidence to date and place in therapy.ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight Fulvestrant for the treatment of endometrial cancer.Report from the 37th san antonio breast cancer symposium, 9-13th december 2014, Texas, USA.The Practicability of a Novel Prognostic Index (PI) Model and Comparison with Nottingham Prognostic Index (NPI) in Stage I-III Breast Cancer Patients Undergoing Surgical Treatment.Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.Advances in the approach to novel drug clinical development for breast cancer.Treatment options in HR⁺/HER2⁻ advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?Mechanisms of hormonal therapy resistance in breast cancer.Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer.Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage.Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.

P2860

Q26741153-7BC38054-DB77-464D-9202-E5565BCCF692 Q26764987-BA4545E7-62C1-4C56-906E-EBDAD93A8257 Q26770482-A8FA773F-BC66-4ADE-94BA-C4760A60CF6E Q26773012-ECD85EBC-2364-4E5D-A58C-D65FFDD61005 Q26777683-1789A8AD-EC39-4C7F-A1D9-874313E22E7E Q26785496-D6C3905D-F098-42FC-94FC-7C546ABB7C0C Q28076777-DF319D75-774A-4A11-9FE8-27B89259C053 Q28077245-18431DD9-38FF-4316-8D17-E8EC695A4F45 Q28077543-4375D642-9761-4DE7-973F-BB437A5905DE Q28080469-7668D702-E4E6-4808-8221-17F200FC286D Q28081872-74C6C3CE-4824-404A-B41A-F7B55A2F5086 Q30251498-4B953773-3C74-4B31-89C0-38F9A7974CBA Q33860545-0686810C-AC7F-446B-B5FE-B3E21F4EDC55 Q33887675-C7A6ECCA-A3F5-4039-91C3-DBC3832CD54A Q33903949-8687B9B3-F63C-4577-A5B4-A5961A6A1A90 Q33915071-6CD18096-DE57-4559-8B36-3AC5C451682E Q34010413-85F62E6A-284E-4F45-A684-456B19FFEA33 Q34514391-D487A19A-9713-4974-8FE0-ECC6894B90E5 Q35106174-9B92CFCD-0400-4439-B23F-A54F91DC18BB Q35850665-748D9DE2-99B0-4F71-AEA2-C84CFC57EAEA Q36279700-FA988E03-BCFB-4B1D-B08C-3778A78A55F0 Q36288939-D8F974B6-CEFB-43F0-A6EF-2B2221635572 Q36534686-AF6AC224-F440-4EEC-8235-E833A8509C62 Q36598699-3552F54A-51B6-4403-AF6C-7D7346A10B91 Q36933778-5DF78984-E413-4700-8B96-601220615229 Q37636799-428D3D8E-4636-4A0B-8922-63636C198BBC Q38206546-D5B37266-CB5B-454D-B357-F5B5F05D43DE Q38250444-B8603C9E-B736-40F9-A1B9-52517962D29E Q38344629-CD899ACA-A375-49FB-86F6-0BF7C490CDA3 Q38374560-528F9DF4-9CBC-4072-A566-E7CD4E0DF54D Q38587521-42DD0D6B-5E9F-42BC-B682-3D4AEE2A0D3F Q38852355-22D7771C-5962-44A9-A9FC-C5F6195C176C Q38880515-DD956908-EF14-4816-96E1-C6C2DAD0B0F8 Q38933237-6795943F-4D61-43B2-A5FF-FE11AF297512 Q39172983-6285F0F0-9F91-42F7-8E9D-4593332B0A64 Q39190569-2A9A465A-5EF5-4772-89A3-CB583F0123F0 Q39227889-5CD0C61E-E78E-44E0-95F1-7C0788DBF1E4 Q39299810-03640727-2883-4776-ACE5-C4EA636BD7EB Q40989080-251BEF01-97D2-441A-B731-A82353556CC5 Q41521650-5C4DD7DB-CDD0-4AD2-A94F-EC17AB9F0F68

P2860

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

http://www.wikidata.org/entity/Q37532641

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

@en

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

@nl

type

label

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

@en

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

@nl

prefLabel

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

@en

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

@nl

P1433

Q37532641-C16D74FC-9658-4114-95A4-DE762769AC45

P1476

Q37532641-5E82D9AA-C5E6-4432-97C6-59103CD639BD

P2093

Q37532641-14BA69D3-AD5E-4AFD-B05C-31A27F2AEC44

Q37532641-3641791F-7ED2-41AA-8E15-AB4CA93862FA

Q37532641-36682314-29C6-4D1C-ADC4-7874BAF0EF89

Q37532641-602986F1-6169-4BA9-9C09-811D3A3BC693

Q37532641-629C1E61-0641-4958-AE50-4F8D4AF1510F

Q37532641-B6C1A2E7-0211-4932-868D-3E722B859404

Q37532641-D589490A-4950-4944-8E73-8F79C05DF35E

Q37532641-E1D66BF7-8865-4CBB-8D60-A2013117B3E4

Q37532641-FAFC2421-7D7C-4598-A441-A60ABF4E67FB

P2860

Q37532641-2069A608-5C81-42B1-8B7F-660BBA0EA34C

Q37532641-21A89D6C-86A9-4929-8B5B-A7675453AA42

Q37532641-303914B2-9CCF-4930-93C1-AE29DB235990

Q37532641-663DA7A1-52E4-4E04-AE7E-A0F635F55A4A

Q37532641-90161357-1CA8-4AF9-93BD-AB2A0879922B

Q37532641-AE1D1CC6-E5DD-4E20-922E-7F6BE4D5C439

Q37532641-AF9CABCC-A712-40EE-875B-4AEE0C0B0870

Q37532641-B398B185-0EDB-47E1-8CC7-A1FAC3630594

Q37532641-C5919DF2-CF34-4E8A-8B06-3A15090AE628

Q37532641-D259DE26-94C8-44D6-8AD1-CCFE79A8ADD7

P304

Q37532641-1902BCF5-D1C6-46B0-8D7B-966D2EC5ED6B

P31

Q37532641-21180C0D-2B3B-4397-9C1E-99619BC07635

P356

Q37532641-94301FD5-CBCD-414C-8E7F-2CA278CF4E3F

P407

Q37532641-3B2BFCDA-C3CD-45E2-B714-2F4AFB8635D3

P433

Q37532641-A1E81D42-34EF-48EE-98A7-31E7021B0A64

P478

Q37532641-08C0F3CD-B75E-41AC-92A6-5E3A1A915CCC

P50

Q37532641-2225CBCD-C59B-494D-A936-B725ADCB9D28

Q37532641-3E313FF4-2334-49A8-A449-A53C425DEDD3

Q37532641-70F9FC90-D3D8-4DE8-B21E-A381C994F026

Q37532641-8CB53DFE-9433-471B-99E8-FB1212074FFA

Q37532641-C19D6E04-BEDB-4252-9D8E-F2A7D00ADBD3

Q37532641-D933BE1C-F472-470B-BF78-316A63F3A098

P577

Q37532641-0DC78CEB-4552-40CA-AD51-FE9E499309D2

P5875

Q37532641-2FE45132-22EC-4E35-8EBE-346A2F51913C

P698

Q37532641-E353D54B-AB43-4C19-B330-40A265D12994

P932

Q37532641-B6CFE365-B4A1-4257-A678-532A34741A1E

P356

P1433

Journal of the National Cancer Institute

P1476

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

@en

P2093

Didier Verhoeven

http://www.w3.org/2001/XMLSchema#string

Guy Jerusalem

http://www.w3.org/2001/XMLSchema#string

Iya Smirnova

http://www.w3.org/2001/XMLSchema#string

José L Pedrini

http://www.w3.org/2001/XMLSchema#string

Kelly Pendergrass

http://www.w3.org/2001/XMLSchema#string

Mikhail R Lichinitser

http://www.w3.org/2001/XMLSchema#string

Roberto Torres

http://www.w3.org/2001/XMLSchema#string

Sally Garnett

http://www.w3.org/2001/XMLSchema#string

Yuri Rukazenkov

http://www.w3.org/2001/XMLSchema#string

P2860

Combination anastrozole and fulvestrant in metastatic breast cancer

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Clinical review: Effect of endocrine therapies on bone in breast cancer patients.

A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.

Fulvestrant (Faslodex) -- how to make a good drug better.

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

P304

djt337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJT337

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Igor N. Bondarenko

Luboš Petruželka

P577

2013-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259247571

http://www.w3.org/2001/XMLSchema#string

P698

24317176

http://www.w3.org/2001/XMLSchema#string

P932

3906991

http://www.w3.org/2001/XMLSchema#string